Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Stabilus Aktie 121550727 / DE000STAB1L8

06.11.2025 12:50:23

EQS-News: Stabilus SE: The Supervisory Board will propose the election of Dr. Frank Heinricht at the 2026 Annual General Meeting

EQS-News: Stabilus SE / Key word(s): Personnel/AGM/EGM
Stabilus SE: The Supervisory Board will propose the election of Dr. Frank Heinricht at the 2026 Annual General Meeting

06.11.2025 / 12:50 CET/CEST
The issuer is solely responsible for the content of this announcement.


CORPORATE NEWS

 

Stabilus SE: The Supervisory Board will propose the election of Dr. Frank Heinricht at the 2026 Annual General Meeting

 

 

Koblenz, November 6, 2025 – The Supervisory Board of Stabilus SE (WKN: STAB1L, ISIN: DE000STAB1L8), one of the world's leading suppliers of motion control solutions for a wide range of industries, today resolved to propose Dr. Frank Heinricht for election to the Supervisory Board at the Annual General Meeting on February 4, 2026.

 

The term of office of Dr. Stephan Kessel, who will not seek re-election after three terms as planned, will expire as of the end of the 2026 Annual General Meeting. After a structured selection process reviewing suitable candidates, the Remuneration and Nomination Committee led by Dr. Ralf-Michael Fuchs therefore proposed Dr. Frank Heinricht for the position. Taking into account both the Supervisory Board’s composition objectives and its overall competence profile and diversity concept, the Supervisory Board has decided to propose the election of Dr. Frank Heinricht at the Annual General Meeting. It is envisaged that, if elected by the Annual General Meeting, Dr. Heinricht will succeed Dr. Stephan Kessel and be elected Chair of the Supervisory Board, subject to the corresponding resolution by the Supervisory Board.

 

Dr. Frank Heinricht has over thirty years of experience within the metal, specialty glass, and electrical industries, having served in a variety of management roles throughout his career. From 2013 to 2024, he held the position of Chair of the Board of Management at Schott AG in Mainz – a technology group specializing in the production of specialty glass and glass-ceramics – where he was responsible for the successful initial public offering of Schott Pharma AG in 2023. Prior to that, he was a member of the Management Board of Heraeus Holding GmbH, one of Germany's top family-owned technology companies in terms of revenue, from 2003 to 2013, most recently as Chair of the Management Board for six years. From 1998 to 2002, he served as the sole Managing Director of ATMEL Germany GmbH, a semiconductor company that is now part of the US-based Microchip Technology group. Dr. Frank Heinricht earned his degree and doctorate in physics from the Technical University of Berlin, then launched his career at Temic Telefunken microelectronic, a manufacturer of semiconductors and automotive electronics.

 

Dr. Frank Heinricht has extensive experience serving on advisory and supervisory boards. He has been Deputy Chair of the Advisory Board of the Würth Group for around 15 years. In addition, he is a member of the advisory board of Schwarz Unternehmenstreuhand KG as well as a member of the supervisory board of B. Braun SE.

 

Dr. Stephan Kessel, Chair of the Supervisory Board of Stabilus SE, said: “I look back with great satisfaction and gratitude on many successful years on the Supervisory Board of Stabilus. During this time, the company has grown both organically and through strategic acquisitions – most recently acquiring Destaco – to become a leading industrial supplier of motion control solutions. These achievements pave the way for continued growth in the future. I am pleased that we will be able to propose Dr. Frank Heinricht, an outstanding candidate for the Supervisory Board, for election at the Annual General Meeting in February 2026. As the long-standing Chair of the Board of Management of Schott AG and Deputy Chair of the Advisory Board of the Würth Group, he would bring extensive expertise and leadership to the Supervisory Board.“

 

Dr. Ralf-Michael Fuchs added: "We have carefully addressed the succession for our long-serving Chairman of the Supervisory Board, Dr. Stephan Kessel, through a structured selection process. We are confident that proposing Dr. Frank Heinricht to the Annual General Meeting as his successor will provide valuable impetus for the further development of Stabilus, thanks to his extensive management experience and broad market and innovation expertise.”

 

The invitation to the Annual General Meeting on February 4, 2026 will be published in mid-December 2025.

 

 

Investor contact:
Andreas Schröder
Tel.: +49 261 8900 8198
E-Mail: anschroeder@stabilus.com
Web: ir.stabilus.com

 

Press contact:
Peter Steiner
Tel.: +49 69 794090 27
E-Mail: stabilus@charlesbarker.de
Charles Barker Corporate Communications

 

About Stabilus

Stabilus is one of the world's leading providers of motion control solutions for a wide range of industries including mobility, industrial machinery, automation, energy, construction, health, leisure and furniture. Stabilus offers reliable and innovative solutions that enable, enhance and automate precise movement, positioning, opening, closing, lifting, lowering and adjusting actions. The Group, which has its headquarters in Koblenz, has a global production and distribution network with eight thousand employees worldwide and generated revenues of €1.3 billion in the 2024 fiscal year. Stabilus SE is listed in the Prime Standard segment of the Frankfurt Stock Exchange and is included in the SDAX index. For more information, see group.stabilus.com and ir.stabilus.com.

 

Important Notice

This press release may contain forward-looking statements based on current assumptions and forecasts made by Stabilus Group management and other information currently available to Stabilus. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

 

 



06.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Stabilus SE
Wallersheimer Weg 100
56070 Koblenz
Germany
Phone: +49 261 8900 0
E-mail: investors@stabilus.com
Internet: group.stabilus.com
ISIN: DE000STAB1L8
WKN: STAB1L
Indices: SDAX
Listed: Regulated Market in Frankfurt; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2224390

 
End of News EQS News Service

2224390  06.11.2025 CET/CEST

Analysen zu Stabilus SE

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
10:36 Stabilus Buy Warburg Research
08:51 Stabilus Overweight JP Morgan Chase & Co.
06.11.25 Stabilus Outperform Bernstein Research
19.09.25 Stabilus Buy Warburg Research
05.08.25 Stabilus Buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest

Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.

Schnell noch Plätze sichern!

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’899.93 20.00 UBSKMU
Short 13’194.70 13.44 SAMB0U
Short 13’680.85 8.75 U9VBSU
SMI-Kurs: 12’429.48 10.11.2025 13:44:26
Long 11’906.86 19.68 SSKBJU
Long 11’650.92 13.98 BAES3U
Long 11’138.16 8.88 BAOSEU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com